EGFR and non-small cell lung carcinoma: For instance, when faced with a patient previously diagnosed with an EGFR-sensitive mutation in non-small cell lung cancer, following radiological progression after first-generation TKI treatment and the detection of the T790M resistance mutation, Deepseek-R1 could potentially recognize the resistance mechanism based on updated clinical information and recommend a treatment switch to osimertinib.